Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2021 1
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Real-world performance of Uromonitor in urothelial bladder cancer detection: a multicentric trial.
Wolff I, Kravchuk AP, Wirtz RM, Schlomm T, Rabien A, Rong D, Hofbauer SL, Labonté FK, Barski D, Otto T, Gössl A, Brookman-May SD, Gilfrich CP, Ecke TH, May M. Wolff I, et al. BJU Int. 2024 Jun 24. doi: 10.1111/bju.16450. Online ahead of print. BJU Int. 2024. PMID: 38923777
RESULTS: Patients with UCB comprised 63.7% (339/532) of the study group. Uromonitor showed a sensitivity, specificity, PPV, NPV, accuracy, and an area-under-the-curve of 49.3%, 93.3%, 92.8%, 51.1%, 65.2%, and 0.713%, respectively. ...CONCLUSION: Despite its innovative appr …
RESULTS: Patients with UCB comprised 63.7% (339/532) of the study group. Uromonitor showed a sensitivity, specificity, PPV, NPV, accu …
Urine-Based Biomarker Test Uromonitor() in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer-A Systematic Review and Meta-Analysis of Diagnostic Test Performance.
Kravchuk AP, Wolff I, Gilfrich C, Wirtz RM, Soares P, Braun KP, Brookman-May SD, Kollitsch L, Hauner K, Burchardt M, Bründl J, Burger M, May M. Kravchuk AP, et al. Cancers (Basel). 2024 Feb 11;16(4):753. doi: 10.3390/cancers16040753. Cancers (Basel). 2024. PMID: 38398144 Free PMC article. Review.
Such UBDTs have not been comprehensively described upon a broad, validated dataset, resulting in cautious guideline recommendations. Uromonitor(), a urine-based DNA-assay detecting hotspot alterations in TERT, FGFR3, and KRAS, shows promising initial results. However, a sy …
Such UBDTs have not been comprehensively described upon a broad, validated dataset, resulting in cautious guideline recommendations. Urom
TERTmonitor-qPCR Detection of TERTp Mutations in Glioma.
Brás JP, Jesus TT, Prazeres H, Lima J, Soares P, Vinagre J. Brás JP, et al. Genes (Basel). 2023 Aug 25;14(9):1693. doi: 10.3390/genes14091693. Genes (Basel). 2023. PMID: 37761833 Free PMC article.
First in Human Subjects Testing of the UroMonitor: A Catheter-free Wireless Ambulatory Bladder Pressure Monitor.
Frainey BT, Majerus SJA, Derisavifard S, Lewis KC, Williams AR, Balog BM, Butler RS, Goldman HB, Damaser MS. Frainey BT, et al. J Urol. 2023 Jul;210(1):186-195. doi: 10.1097/JU.0000000000003451. Epub 2023 Jun 9. J Urol. 2023. PMID: 37293725
The UroMonitor was also easily inserted and removed in all subjects. The UroMonitor reproduced bladder pressure, capturing 98% (85/87) of voiding and nonvoiding urodynamic events. All subjects voided with only the UroMonitor in place with low post-void residu …
The UroMonitor was also easily inserted and removed in all subjects. The UroMonitor reproduced bladder pressure, capturing 98% …
Surveillance of Low-Grade Non-Muscle Invasive Bladder Tumors Using Uromonitor: SOLUSION Trial.
Azawi N, Vásquez JL, Dreyer T, Guldhammer CS, Saber Al-Juboori RM, Nielsen AM, Jensen JB. Azawi N, et al. Cancers (Basel). 2023 Apr 17;15(8):2341. doi: 10.3390/cancers15082341. Cancers (Basel). 2023. PMID: 37190269 Free PMC article.
Uromonitor showed a sensitivity of 89.7%, specificity of 96.2%, PPV of 72.9%, and NPV of 98.8%. In 28 cases, flexible cystoscopy was falsely positive, leading to surgery, where Uromonitor showed negative results. There were 13 cases of possible false positives for
Uromonitor showed a sensitivity of 89.7%, specificity of 96.2%, PPV of 72.9%, and NPV of 98.8%. In 28 cases, flexible cystoscopy was
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis.
Laukhtina E, Shim SR, Mori K, D'Andrea D, Soria F, Rajwa P, Mostafaei H, Compérat E, Cimadamore A, Moschini M, Teoh JY, Enikeev D, Xylinas E, Lotan Y, Palou J, Gontero P, Babjuk M, Witjes JA, Kamat AM, Roupret M, Shariat SF, Pradere B; European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Laukhtina E, et al. Eur Urol Oncol. 2021 Dec;4(6):927-942. doi: 10.1016/j.euo.2021.10.003. Epub 2021 Nov 6. Eur Urol Oncol. 2021. PMID: 34753702 Free article. Review.
EVIDENCE ACQUISITION: PubMed, Web of Science, and Scopus were searched up to April 2021 to identify studies addressing the diagnostic values of UBTs: Xpert bladder cancer, Adxbladder, Bladder EpiCheck, Uromonitor and Cxbladder Monitor, and Triage and Detect. The primary en …
EVIDENCE ACQUISITION: PubMed, Web of Science, and Scopus were searched up to April 2021 to identify studies addressing the diagnostic values …
Clinical Validation of a Urine Test (Uromonitor-V2()) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients.
Sieverink CA, Batista RPM, Prazeres HJM, Vinagre J, Sampaio C, Leão RR, Máximo V, Witjes JA, Soares P. Sieverink CA, et al. Diagnostics (Basel). 2020 Sep 24;10(10):745. doi: 10.3390/diagnostics10100745. Diagnostics (Basel). 2020. PMID: 32987933 Free PMC article.
The aim of this study was to investigate the Uromonitor-V2()'s performance in detecting NMIBC recurrence and compare it with urine cytology. ...Urine cytology was available for 52 patients, and the sensitivity, specificity, PPV, and NPV were 26.3%, 90.9%, 62.5%, and 68.2%, …
The aim of this study was to investigate the Uromonitor-V2()'s performance in detecting NMIBC recurrence and compare it with urine cy …
Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study.
Batista R, Vinagre J, Prazeres H, Sampaio C, Peralta P, Conceição P, Sismeiro A, Leão R, Gomes A, Furriel F, Oliveira C, Torres JN, Eufrásio P, Azinhais P, Almeida F, Gonzalez ER, Bidovanets B, Ecke T, Stinjs P, Pascual ÁS, Abdelmalek R, Villafruela A, Beardo-Villar P, Fidalgo N, Öztürk H, Gonzalez-Enguita C, Monzo J, Lopes T, Álvarez-Maestro M, Servan PP, De La Cruz SMP, Perez MPS, Máximo V, Soares P. Batista R, et al. Front Genet. 2019 Dec 18;10:1237. doi: 10.3389/fgene.2019.01237. eCollection 2019. Front Genet. 2019. PMID: 31921291 Free PMC article.
Based on these, we developed an ultra-sensitive, urine-based assay called Uromonitor(), capable of detecting trace amounts of TERT promoter (c.1-124C > T and c.1-146C > T) and FGFR3 (p.R248C and p.S249C) hotspot mutations, in tumor cells exfoliated to urine samples. …
Based on these, we developed an ultra-sensitive, urine-based assay called Uromonitor(), capable of detecting trace amounts of TERT pr …